Due to the observed overexpression of VEGF-A in prostate cancer, coupled with its correlation with an unfavorable prognosis and metastasis, the majority of clinical investigations into anti-angiogenic approaches for prostate cancer have revolved around the inhibition of VEGF-A [143]. This evidence concerns the gene VEGFA and prostate cancer.